Showing results (41-50 of 48) with videos related to
Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Journal of Medicinal Chemistry|January 16, 2020
Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic SteatohepatitisDonatella Chianelli, Paul V Rucker, Jason Roland, et al.Nature|January 15, 2010
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitorsJianming Zhang, Francisco J Adrián, Wolfgang Jahnke, et al.Nature|August 9, 2016
Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sicknessShilpi Khare, Advait S Nagle, Agnes Biggart, et al.Journal of Medicinal Chemistry|June 8, 2013
Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trialsThomas H Marsilje, Wei Pei, Bei Chen, et al.Journal of Medicinal Chemistry|February 21, 2020
Selective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes: Discovery of 6-Azaindole Derivative GNF2133Yahu A Liu, Qihui Jin, Yefen Zou, et al.Nature|November 29, 2013
Targeting Plasmodium PI(4)K to eliminate malariaCase W McNamara, Marcus Cs Lee, Chek Shik Lim, et al.Journal of Medicinal Chemistry|July 16, 2020
Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of LeishmaniasesAdvait Nagle, Agnes Biggart, Celine Be, et al.Journal of Medicinal Chemistry|May 19, 2026
Targeting Multiple KRAS Mutations with High-Affinity Macrocyclic Inhibitors: From Discovery to Preclinical ValidationDean P Phillips, Phil B Alper, Charles Y Cho, et al.Pageof 5